PROGRESSING DIRECTED THERAPIES USING MOLECULAR IMAGING

Abstract

The clinical studies that are using fluorine-18 tracers succumb to four general sorts: treatment planning, either for
pharmaceutical therapy or radiation therapy; prescient or reaction marker studies for new pharmaceutical utilizing
established tracer; development of new tracer for clinical-sickness diagnosis; and improvement of new biomarker for pharmaceutical therapy. The foremost two include tracers with past clinical experience while the recent incorporate various Phase 1 studies to confirm the safety, dosimetry, and best imaging parameters of a new tracer. The clinical provision may be to utilize the new tracer as an affirmed demonstrative apparatus for ailment diagnosis or for use as a clinical research and development tool. The last classification represents for the most active zone, an impression of the solid interest in the utilization of fluorine-18 PET imaging in drug development and discovery.
KEYWORDS: PET imaging, Electrophilic, Fluorine-18-fluorodeoxyglucose, FDA